Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

Postoperative adjuvant chemotherapy followed by immunotherapy for non-small cell lung cancer has become a new treatment recommendation, but there are still many clinical problems to be solved in postoperative adjuvant immunotherapy. This study aims to explore the efficacy and safety of adjuvant chemotherapy combined with immunotherapy in patients with stage IIA-IIIA non-small cell lung cancer after surgery. Patients who meet the protocol and sign the informed consent form received 4 cycles of chemotherapy combined with camrelizumab, followed by maintenance with camrelizumab until one year or t

Trial Details

NCT ID
NCT05825443
Phase
PHASE2
Sponsor
Nanfang Hospital, Southern Medical University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Camrelizumab
Locations (sample)
  • Guandong, Guangdong, China

Key Eligibility Criteria

  • Sign the informed consent form before starting the study;
  • For patients with non-small cell lung cancer who have undergone surgical resection, the TNM stage after surgery is IIA-IIIA;
  • Patients cannot receive targeted adjuvant therapy;
  • 18-80 years old;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →